| Dosage form | Process | Raw materials | Characteristics of the product | Ref. no. |
|---|---|---|---|---|
| Ofloxacin-loaded pellets | Extrusion-spheronization | Ethyl cellulose, sodium bicarbonate, Eudragit RL 30D | Floats and retards the release over 8 h | [13] |
| Norfloxacin Microballoons | Emulsion solvent diffusion | Eudragit®L100, Eudragit®RS 100 | Intestinal pH dependent release | [14] |
| Bumetanide pellets | Fluid bed layering and coating | Eudragit®RS 100, Tri ethyl citrate, sodium chloride | Porous nature with sustained release | [15] |
| Levodopa novel unfolded CR-GRDF | Solvent evaporation | Gelatin, L-polylactic acid, ethyl cellulose, carbidopa, Eudragit®S 100 | Sustained drug release over 9 h | [16] |
| Novel floating effervescent | Ion exchange resins | Eudragit®RS 100 and sodium bi carbonate | Floated over 24 h | [17] |
| Diclofenac potassium pellets | Extrusion–spheronization | Eudragit®NE 30D, Eudragit®RS 30D and Kollicoat®SR 30D | Controls the release and fluctuations | [18] |
| Metformin hydrochloride matrix tablets | Direct compression | Polyethylene oxide and Eudragit®L100 | Unaffected by gastric pH | [19] |
| Levodopa floating coated mini-tabs | Melt granulation and compression | Eudragit®RL 30D, acetyl tri ethyl citrate | Buoyancy over 13 h and sustained release over 20 h | [20] |
| Riboflavin unfolding dosage form | Accordion pill technology | Eudragit® L and Eudragit® S plasticized with tri ethyl citrate | prolongs the gastric residence time | [21] |
| Diltiazem hydrochloride floating microspheres | Ionotropic gelation method | sodium alginate, calcium chloride, calcium carbonate, Eudragit®RS 30D and chitosan | Excellent floating ability with suitable drug release pattern over 24 h | [22] |
| Rabeprazole sodium enteric coated tablet | Wet granulation and direct compression | Colorcoat EC4S, Mannitol SD 200, microcrystalline cellulose and kollidon CL | Provides resistance to acidic environment and facilitates sustained release in alkaline conditions | [23] |
| Matrix tablet | Direct compression | Kollidon SR, Propanolol hydrochloride | Sustained the release over 24 h with fickian diffusion | [24] |
| Riboflavin microballoon | Emulsion solvent diffusion | Eudragit®RS 100 and hydroxyl propyl methyl cellulose | Urinary excretion was sustained | [25] |
| Ketoprofen floating microparticles | Emulsion solvent diffusion | Eudragit®S 100 and Eudragit®RL 100 | Gave higher percentage yield and better buoyancy | [26] |
| Riboflavin microballoons | Emulsion solvent diffusion | Eudragit®S 100, HPMC, PVA, dichloro methane and ethanol | Drug release from microballoons and total urinary excretion were strongly correlated | [27] |
| Verapamil floating pellets | Wet granulation and spheronization | Povidone K 30, Eudragit®NE 30 D, Eudragit®L 30 D, triethyl citrate, talcum | Floated for 6 h and gave improved pharmacokinetics than the conventional tablet | [28] |
| Microballoons | Emulsion solvent diffusion | Eudragit®S 100 and monostearin | Optimum temperature of 40 °C gave better buoyancy and retarded release due to smooth surface. Drug entrapment was high due to higher distribution coefficient | [29] |
| Riboflavin microballoons | Emulsion solvent diffusion | Eudragit®RS 100 and HPMC | Gamma scintigraphy technique confirms that the floating microballoons retained for longer time period in comparison to the non-floating in fed conditions, both half life and the total urinary excretion of drug increases significantly | [30] |
| Avidin microstructured Delivery | Microfabrication technology | Poly (methyl methacrylate) (PMMA) and Lectin | Adheres to the intestinal mucosa, prevents drug degradation and sustains the release | [32] |